0.313
-0.03 (-7.67%)
| Previous Close | 0.339 |
| Open | 0.337 |
| Volume | 883,905 |
| Avg. Volume (3M) | 6,350,955 |
| Market Cap | 7,205,395 |
| Price / Earnings (Forward) | 2.97 |
| Price / Sales | 5.54 |
| Price / Book | 1.28 |
| 52 Weeks Range | |
| Earnings Date | 28 Aug 2025 - 1 Sep 2025 |
| Operating Margin (TTM) | -1,127.37% |
| Quarterly Revenue Growth (YOY) | 15.50% |
| Total Debt/Equity (MRQ) | 1.91% |
| Current Ratio (MRQ) | 4.38 |
| Operating Cash Flow (TTM) | -7.64 M |
| Levered Free Cash Flow (TTM) | -4.82 M |
| Return on Assets (TTM) | -53.18% |
| Return on Equity (TTM) | -134.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Can-Fite Biopharma Ltd Sponsore | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.25 |
|
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Institutions | 1.16% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sabby Management, Llc | 30 Sep 2025 | 1,406,050 |
| Rhumbline Advisers | 30 Sep 2025 | 57,932 |
| Bogart Wealth, Llc | 30 Sep 2025 | 15,045 |
| Captrust Financial Advisors | 30 Sep 2025 | 11,375 |
| Two Sigma Securities, Llc | 30 Sep 2025 | 10,642 |
| Fifth Third Bancorp | 30 Sep 2025 | 3,000 |
| Costello Asset Management, Inc | 30 Sep 2025 | 1,000 |
| Activest Wealth Management | 30 Sep 2025 | 200 |
| Avion Wealth | 30 Sep 2025 | 100 |
| Eversource Wealth Advisors, Llc | 30 Sep 2025 | 68 |
| Td Waterhouse Canada Inc. | 30 Sep 2025 | 20 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Nov 2025 | Announcement | Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference |
| 24 Nov 2025 | Announcement | Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference |
| 20 Nov 2025 | Announcement | Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil |
| 18 Nov 2025 | Announcement | Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson |
| 15 Sep 2025 | Announcement | Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 12 Nov 2013 | - | 25 Nov 2013 | 0.169622 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2013 | 0.170 | 1 | 0.02 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |